Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment-Reference-Cited by-同舟云学术

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Published:2022-08-29 Issue:6 Volume:47 Page:817-825
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Viswanathan Lakshmi,Bachman Eric,Tian Simon,Ahluwalia Neil,Zhang Yaohua,Bernstein Harold S.,Panorchan Paul

Funder

Vertex Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-022-00791-8.pdf

Reference26 articles.

1. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124.

2. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–31.

3. Cystic Fibrosis Foundation. 2019 Patient registry annual data report. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report/. Accessed 3 Sep 2021.

4. ECFS. 2018 Patient registry annual report. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf. Accessed 3 Sep 2021.

5. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121;Journal of Clinical Investigation;2024-07-02

2. Management of liver disease and portal hypertension in cystic fibrosis: a review;Expert Review of Respiratory Medicine;2024-05-03

3. SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium;Pediatric Pulmonology;2024-04-12

4. Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease;Journal of Cystic Fibrosis;2024-04

5. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series;Clinical Therapeutics;2023-12